Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...

Partnership includes the development of combination products, including a fixed-dose combination of petrelintide and Roche’s dual GLP-1/GIP receptor agonist, CT-388, for weight management.

The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.

Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a ...

Roche (RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global ...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...